ICON plc (ICLR) Stock Analysis
Recovery setup
Healthcare · Diagnostics & Research
Wait for pullback to $106.65. BUY gates pass at $116.17, but analyst target reached - limited upside remaining and value-trap signals (2/5): Revenue declining (-14.1% YoY), Margin compression (op margin 4.8%) argue for a more patient entry. Engine's entry $106.65 (Ma50 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum.
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of... Read more
Wait for pullback to $106.65. BUY gates pass at $116.17, but analyst target reached - limited upside remaining and value-trap signals (2/5): Revenue declining (-14.1% YoY), Margin compression (op margin 4.8%) argue for a more patient entry. Engine's entry $106.65 (Ma50 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: Death cross but MACD improving, RSI 60. Earnings in 0 days. Wait until post-earnings. Score 4.7/10, moderate confidence.
Passes 5/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 0d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $106.65. BUY gates pass at $116.17, but analyst target reached - limited upside remaining and value-trap signals (2/5): Revenue declining (-14.1% YoY), Margin compression (op margin 4.8%) argue for a more patient entry. Engine's entry $106.65 (Ma50 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: Death cross but MACD improving, RSI 60. Earnings in 0 days. Wait until post-earnings. Target $118.61 (+2.1%), stop $94.16 (−23.4%), Setup A.R:R 1.6:1. Score 4.7/10, moderate confidence.
Take-profit target: $118.61 (+11.2% upside). Target $118.61 (+2.1%), stop $94.16 (−23.4%), Setup A.R:R 1.6:1. Stop-loss: $94.16.
Analyst target reached - limited upside remaining; Value-trap signals (2/5): Revenue declining (-14.1% YoY), Margin compression (op margin 4.8%).
ICON plc trades at a P/E of 15.7 (forward 9.5). TrendMatrix value score: 7.3/10. Verdict: Buy (Wait for Entry).
24 analysts cover ICLR with a consensus score of 3.8/5. Average price target: $133.
What does ICON plc do?ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization...
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.